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Case 1
An 82 year old female with a history of ductal carcinoma in situ of the left breast in 1985, treated with 
excision and radiation therapy at that time, presented in July of 2003 with a shrunken and ﬁ  rm left 
breast and multiple erythematous papules on the skin. Biopsy showed an estrogen and progesterone 
receptor positive, invasive lobular carcinoma. Bilateral mammograms were negative as well as CT 
scans of the chest, abdomen and pelvis. Letrozole was initiated and the patient experienced stable 
disease until July of 2004 when progression was noted. Hormonal therapy was switched to Tamoxifen, 
and the patient initially experienced a partial response and then had stable disease until May of 2005 
at which time progressive disease was noted again with multiple new nodules over the left breast and 
chest wall (Fig. 1). Metastatic workup was again negative. Patient was started on 850 mg/m
2 of single 
agent capecitabine twice a day, on a 14 out of 28 day schedule modiﬁ  ed for her advanced age, creatinine 
clearance of 18 and chronic cytopenias, but developed renal insufﬁ  ciency and grade 2 diarrhea. 
Capecitabine was further modiﬁ  ed to 700 mg/m
2 on a 5 day out of 28 day cycle, which she tolerated 
much better. Despite dose reduction she experienced a signiﬁ  cant response after only 2 cycles and had 
no progression after 10 cycles of treatment (March 2006) at which time Capecitabine was discontinued 
due to progressive renal insufﬁ  ciency (Fig. 2). The patient experienced no progression until another 
7 months when disease was found in the liver and hospice care was initiated. She expired 6 months 
later (June, 2007).
Case 2
A 61 year old female was diagnosed with an estrogen and progesterone receptor positive stage II breast 
cancer of the right breast in 1995. She was initially treated with modiﬁ  ed radical mastectomy, 6 cycles 
of adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil followed by 5 years of adjuvant 
Tamoxifen. In late 2003 patient was found to have biopsy proven recurrence in a right supraclavicular 
node and CT showed a soft tissue mass in the right axillary area. Palliative treatment with Anastrozole 
was initiated and the patient experienced a clinical response. In October of 2004 CT scan showed 
enlargement of the axillary mass. The patient was treated with 6600 cGy of radiation therapy with 
weekly Taxol as radiosensitizer. Her hormonal therapy was switched to Exemestane. Patient was found 
to have progressive disease in May of 2005 when several ﬁ  rm subcutaneous nodules were detected in 
the right axillary fold and lateral chest wall. Patient was started on capecitabine 1500 mg/m
2 twice a 
day on a 14 day every 21 day schedule and had to be gradually modiﬁ  ed to a 14 days every 5 week 
schedule due to cytopenias. Signiﬁ  cant response was seen clinically after 2 cycles, a complete response 
was observed after 3 cycles and the patient remained without progression for 14 months (10 cycles) 
during which time progression was noted. She experienced grade 1 fatigue, alopecia and stomatitis as 
well as grade 1 hand-foot syndrome which improved with gradual modiﬁ  cation of the regiment. After 
progression she was sequentially treated with single agent gemcitabine (partial response) and 
examestane (no response) before initiating hospice care fore the last 6 months of her life and expiring 
in December 2007.416
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Discussion
Excluding malignant melanoma, breast cancer has 
the highest incidence of cutaneous metastasis com-
pared to any other solid malignancy. Autopsy studies 
reported an estimated incidence of 24%.
1 In a review 
on 420 patients with cutaneous metastatic disease by 
Lookingbill et al. 70.7% of the skin metastasis in 
female patients were from breast cancer.
2
The clinical presentation varies as 80% of the 
lesions are papules and nodules and 11% are tel-
angiectatic carcinoma.
3 Other presentations include 
erysipeloid carcinoma, “en cuirasse carcinoma”, 
alopecia neoplastica, zosteriform pattern, and 
melanoma like pigmented lesions.
3–5
In a review of 164 cases of breast cancer with 
cutaneous metastasis conducted by Mordenti et al., 
the commonest anatomic sites involved were the 
sites of previous mastectomy and the anterior aspect 
of the chest.
3 These two locations compromised 
over three quarters of the cases studied. Less com-
mon sites included the axilla, back, scalp, periau-
ricular area, supraclavicular area, face, neck, and 
upper and lower extremities. In the study by Look-
ingbill et al., there was a greater variability in the 
distribution of metastatic disease by anatomic loca-
tion.
2 The eyelids have also been found to be targets 
for metastatic breast disease (carcinomatosis 
blepharitis).
6
Little is known on speciﬁ  c treatment of metastatic 
breast cancer to the skin and thus systemic treatment 
modalities for metastatic breast cancer in general 
are routinely employed. Surgery and radiation 
therapy are usually avoided (unless in the palliative 
setting) since skin metastasis is commonly an 
indication of more advanced disease. This is not true 
however when dealing with isolated locoregional 
recurrence, which occurs anywhere from 2.3% to 
14% of women treated today for localized breast 
cancer, depending on the modality of treatment 
(mastectomy versus lumpectomy and radiation).
7,8 
Locoregional recurrence can occur anywhere from 
months to over 10 years following primary therapy, 
and surgical treatment can result in significant 
disease free survival. When locoregional recurrence 
involves primarily the skin, as for example the site 
of the surgical scar, surgical therapy (such as 
mastectomy if a lumpectomy was earlier performed) 
is standard and re-irradiation of the chest wall is not 
uncommon.
9 Frequently however, the skin 
involvement is a direct extension of a deeper 
primary, and when the chest wall is involved, a full 
thickness chest wall excision is usually performed.
Although this approach can cure a few women, there 
can be significant complications with direct 
implications in quality of life.
10,11 Occasionally such 
extensive chest wall operations have been performed 
in the palliative setting in women with known 
metastatic disease to other organs.
12
In general a single cutaneous lesion is associated 
with a better prognosis than multiple metastatic 
sites. In a study by Fentiman et al., 22% of patients 
with a single cutaneous lesion survived over 
10 years.
13 Photodynamic therapy has been 
employed in the treatment of cutaneous metastasis 
of breast cancer with complete response rates rang-
ing from 13.5% to 40%.
14,15 However, candidates 
for photodynamic therapy usually exhibit only 
small volume disease. In one study 16 skin lesions 
in 12 patients were treated with intralesional inter-
feron alpha injections with 7 complete responses 
and 7 partial responses.
16
Topical agents have also been tested with poor 
to minor results. Miltefosine, a topical cytostatic 
agent, was applied in 25 patients with skin metas-
tasis and a 36% response rate was observed. How-
ever, the majority of the responses were minor.
17 
In another study topical ceramides yielded a partial 
response in only one of 25 patients with cutaneous 
breast cancer.
18
No particular systemic treatment has been sug-
gested speciﬁ  cally for cutaneous metastatic breast 
cancer. Capecitabine has shown a response rate 
ranging from 15% to 28% in the setting of meta-
static breast cancer in general with complete 
response rates ranging from 1%–4%.
19–22 In these 
studies, the incidence of cutaneous metastasis is 
either not provided,
19,20 or when provided, the 
response of the skin lesions are not described 
separately (25% of 136 patients had skin lesions 
in the study by Reichardt et al.).
21
Our two patients who received capecitabine 
showed a dramatic response with resolution of their 
skin lesions that lasted over a year. There is no 
evidence to suggest that capecitabine has particular 
activity against cutaneous metastasis from breast 
cancer. However, we believe that these two cases 
could potentially encourage documentation of 
cutaneous speciﬁ  c responses from capecitabine.
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